Zhenjian Xu1,2, Ying Tang3, Qiuyan Huang1,2, Sha Fu1,2, Xiaomei Li1,2, Baojuan Lin1,2, Anping Xu4,5, Junzhe Chen6,7. 1. Department of Nephrology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, 510120, China. 2. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, 510120, China. 3. Department of Nephrology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, 510630, China. 4. Department of Nephrology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, 510120, China. xuanping@mail.sysu.edu.cn. 5. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, 510120, China. xuanping@mail.sysu.edu.cn. 6. Department of Nephrology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, 510120, China. chenjzh23@mail.sysu.edu.cn. 7. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, 510120, China. chenjzh23@mail.sysu.edu.cn.
Abstract
BACKGROUND: Acute kidney injury (AKI) occurs among patients with coronavirus disease-19 (COVID-19) and has also been indicated to be associated with in-hospital mortality. Remdesivir has been authorized for the treatment of COVID-19. We conducted a systematic review to evaluate the incidence of AKI in hospitalized COVID-19 patients. The incidence of AKI in different subgroups was also investigated. METHODS: A thorough search was performed to find relevant studies in PubMed, Web of Science, medRxiv and EMBASE from 1 Jan 2020 until 1 June 2020. The systematic review was performed using the meta package in R (4.0.1). RESULTS: A total of 16,199 COVID-19 patients were included in our systematic review. The pooled estimated incidence of AKI in all hospitalized COVID-19 patients was 10.0% (95% CI: 7.0-12.0%). The pooled estimated proportion of COVID-19 patients who needed continuous renal replacement therapy (CRRT) was 4% (95% CI: 3-6%). According to our subgroup analysis, the incidence of AKI could be associated with age, disease severity and ethnicity. The incidence of AKI in hospitalized COVID-19 patients being treated with remdesivir was 7% (95% CI: 3-13%) in a total of 5 studies. CONCLUSION: We found that AKI was not rare in hospitalized COVID-19 patients. The incidence of AKI could be associated with age, disease severity and ethnicity. Remdesivir probably did not induce AKI in COVID-19 patients. Our systematic review provides evidence that AKI might be closely associated with SARS-CoV-2 infection, which should be investigated in future studies.
BACKGROUND:Acute kidney injury (AKI) occurs among patients with coronavirus disease-19 (COVID-19) and has also been indicated to be associated with in-hospital mortality. Remdesivir has been authorized for the treatment of COVID-19. We conducted a systematic review to evaluate the incidence of AKI in hospitalized COVID-19patients. The incidence of AKI in different subgroups was also investigated. METHODS: A thorough search was performed to find relevant studies in PubMed, Web of Science, medRxiv and EMBASE from 1 Jan 2020 until 1 June 2020. The systematic review was performed using the meta package in R (4.0.1). RESULTS: A total of 16,199 COVID-19patients were included in our systematic review. The pooled estimated incidence of AKI in all hospitalized COVID-19patients was 10.0% (95% CI: 7.0-12.0%). The pooled estimated proportion of COVID-19patients who needed continuous renal replacement therapy (CRRT) was 4% (95% CI: 3-6%). According to our subgroup analysis, the incidence of AKI could be associated with age, disease severity and ethnicity. The incidence of AKI in hospitalized COVID-19patients being treated with remdesivir was 7% (95% CI: 3-13%) in a total of 5 studies. CONCLUSION: We found that AKI was not rare in hospitalized COVID-19patients. The incidence of AKI could be associated with age, disease severity and ethnicity. Remdesivir probably did not induce AKI in COVID-19patients. Our systematic review provides evidence that AKI might be closely associated with SARS-CoV-2 infection, which should be investigated in future studies.
Authors: Sabue Mulangu; Lori E Dodd; Richard T Davey; Olivier Tshiani Mbaya; Michael Proschan; Daniel Mukadi; Mariano Lusakibanza Manzo; Didier Nzolo; Antoine Tshomba Oloma; Augustin Ibanda; Rosine Ali; Sinaré Coulibaly; Adam C Levine; Rebecca Grais; Janet Diaz; H Clifford Lane; Jean-Jacques Muyembe-Tamfum; Billy Sivahera; Modet Camara; Richard Kojan; Robert Walker; Bonnie Dighero-Kemp; Huyen Cao; Philippe Mukumbayi; Placide Mbala-Kingebeni; Steve Ahuka; Sarah Albert; Tyler Bonnett; Ian Crozier; Michael Duvenhage; Calvin Proffitt; Marc Teitelbaum; Thomas Moench; Jamila Aboulhab; Kevin Barrett; Kelly Cahill; Katherine Cone; Risa Eckes; Lisa Hensley; Betsey Herpin; Elizabeth Higgs; Julie Ledgerwood; Jerome Pierson; Mary Smolskis; Ydrissa Sow; John Tierney; Sumathi Sivapalasingam; Wendy Holman; Nikki Gettinger; David Vallée; Jacqueline Nordwall Journal: N Engl J Med Date: 2019-11-27 Impact factor: 91.245
Authors: R Maan; S H Al Marzooqi; J S Klair; J Karkada; O Cerocchi; M Kowgier; S M Harrell; K D Rhodes; H L A Janssen; J J Feld; A Duarte-Rojo Journal: Aliment Pharmacol Ther Date: 2017-05-03 Impact factor: 8.171
Authors: Jonathan Grein; Norio Ohmagari; Daniel Shin; George Diaz; Erika Asperges; Antonella Castagna; Torsten Feldt; Gary Green; Margaret L Green; François-Xavier Lescure; Emanuele Nicastri; Rentaro Oda; Kikuo Yo; Eugenia Quiros-Roldan; Alex Studemeister; John Redinski; Seema Ahmed; Jorge Bernett; Daniel Chelliah; Danny Chen; Shingo Chihara; Stuart H Cohen; Jennifer Cunningham; Antonella D'Arminio Monforte; Saad Ismail; Hideaki Kato; Giuseppe Lapadula; Erwan L'Her; Toshitaka Maeno; Sumit Majumder; Marco Massari; Marta Mora-Rillo; Yoshikazu Mutoh; Duc Nguyen; Ewa Verweij; Alexander Zoufaly; Anu O Osinusi; Adam DeZure; Yang Zhao; Lijie Zhong; Anand Chokkalingam; Emon Elboudwarej; Laura Telep; Leighann Timbs; Ilana Henne; Scott Sellers; Huyen Cao; Susanna K Tan; Lucinda Winterbourne; Polly Desai; Robertino Mera; Anuj Gaggar; Robert P Myers; Diana M Brainard; Richard Childs; Timothy Flanigan Journal: N Engl J Med Date: 2020-04-10 Impact factor: 91.245
Authors: Sarah Lim; Debra A DeBruin; Jonathon P Leider; Nneka Sederstrom; Ruth Lynfield; Jason V Baker; Susan Kline; Sarah Kesler; Stacey Rizza; Joel Wu; Richard R Sharp; Susan M Wolf Journal: Mayo Clin Proc Date: 2020-06-20 Impact factor: 7.616
Authors: Carlos K H Wong; Ivan C H Au; Wing Yiu Cheng; Kenneth K C Man; Kristy T K Lau; Lung Yi Mak; Sing Leung Lui; Matthew S H Chung; Xi Xiong; Eric H Y Lau; Benjamin J Cowling Journal: Aliment Pharmacol Ther Date: 2022-03-22 Impact factor: 9.524
Authors: Tahereh Sabaghian; Amir Behnam Kharazmi; Ali Ansari; Fatemeh Omidi; Seyyedeh Neda Kazemi; Bahareh Hajikhani; Roya Vaziri-Harami; Ardeshir Tajbakhsh; Sajjad Omidi; Sara Haddadi; Amir Hashem Shahidi Bonjar; Mohammad Javad Nasiri; Mehdi Mirsaeidi Journal: Front Med (Lausanne) Date: 2022-04-04
Authors: Denise Battaglini; Chiara Robba; Andrea Fedele; Sebastian Trancǎ; Samir Giuseppe Sukkar; Vincenzo Di Pilato; Matteo Bassetti; Daniele Roberto Giacobbe; Antonio Vena; Nicolò Patroniti; Lorenzo Ball; Iole Brunetti; Antoni Torres Martí; Patricia Rieken Macedo Rocco; Paolo Pelosi Journal: Front Med (Lausanne) Date: 2021-06-04